Biopolymer-based tumor microenvironment-responsive nanomedicine for targeted cancer therapy

Nanomedicine (Lond). 2024 Mar;19(7):633-651. doi: 10.2217/nnm-2023-0302. Epub 2024 Mar 6.

Abstract

Nanomedicine has opened up new avenues for cancer treatment by enhancing drug solubility, permeability and targeted delivery to cancer cells. Despite its numerous advantages over conventional therapies, nanomedicine may exhibit off-target drug distribution, harming nontarget regions. The increased permeation and retention effect of nanomedicine in tumor sites also has its limitations, as abnormal tumor vasculature, dense stroma structure and altered tumor microenvironment (TME) may result in limited intratumor distribution and therapeutic failure. However, TME-responsive nanomedicine has exhibited immense potential for efficient, safe and precise delivery of therapeutics utilizing stimuli specific to the TME. This review discusses the mechanistic aspects of various TME-responsive biopolymers and their application in developing various types of TME-responsive nanomedicine.

Keywords: biopolymers; cancer therapy; stimuli-responsive; targeted nanomedicine; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Drug Delivery Systems
  • Humans
  • Nanomedicine*
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Tumor Microenvironment